Diagnostic Hybrids Sponsored Gravesí Disease Foundationís Patient and Family Education Conference

November 18, 2009


Athens, Ohio – On October 16, 2009, Diagnostic Hybrids was a presenting corporate sponsor at the 2009 Graves’ Patient and Family Education Conference of the Graves’ Disease Foundation. The Graves’ Disease Foundation is an international nonprofit organization focused on Graves’ disease and other thyroid-related diseases for education and research. Diagnostic Hybrids’ sponsorship allows the Foundation to increase patient educational services and expand the conference program.

“Diagnostic Hybrids is committed to improving Graves’ disease diagnostics. This commitment will have a positive impact on the lives of people affected by the disease,” said Jeff Houtz, Senior Product Manager for Diagnostic Hybrids’ thyroid testing products. “The partnership with the Graves’ Disease Foundation will allow us to directly interact with those involved in gathering vital knowledge from Graves’ disease research and treatment, while supporting an organization that has made great strides in Graves’ disease education and awareness,” Houtz added.

A ceremonial check was presented by David R. Scholl, Ph.D., President & CEO of Diagnostic Hybrids, to Nancy H Patterson, Board Chair & Peter Filocamo, President & CEO of the Graves’ Disease Foundation, at their national Patient & Family Education Conference in Charlotte, N.C. The Foundation also received a matching gift from the Bell Charitable Foundation.

Diagnostic Hybrids recently launched the ThyretainTM TSI Reporter BioAssay, the first FDA-cleared test that specifically detects thyroid stimulating immunoglobulin in patient serum. Thyretain is to be used as an aid in the differential diagnosis of Graves’ disease, an autoimmune thyroid disorder that affects 1-2% of the population1 and can be difficult to diagnose due to nonspecific early symptoms.

“This gift from Diagnostic Hybrids to the Graves’ Disease Foundation is a major step towards our ‘Campaign for a Cure’ of Graves’ disease,” said Filocamo, adding that “the Foundation is enthusiastic about continuing the partnership with Diagnostic Hybrids to help those who are afflicted with thyroid and autoimmune diseases. Together we will advocate for the millions of people affected that it’s time to take Graves’ disease seriously!”

The Graves’ Disease Foundations’ mission is threefold: to support research into the cause of and cures for Graves’ thyroid disease, to improve quality of life for people with Graves’ disease and those who care for them, and to educate patients, caregivers and the public about Graves’ disease and its treatment. For more information, please visit www.ngdf.org.

About Diagnostic Hybrids
Diagnostic Hybrids invents, develops, manufactures, and sells innovative diagnostic and analytical products for a wide range of viral respiratory diseases, herpes virus infections, and other specific viral and thyroid diseases. The company also develops and commercializes innovative and genetically engineered cell-based detection products for the pharmaceutical and biotechnology industry, with an initial focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines. The company is certified to ISO 13485 standards and manufactures live continuous and primary cell cultures for clinical diagnostics and pharmacology assays from its headquarters in Athens, OH. Diagnostic Hybrids was named one of the 500 Fastest Growing Companies in America in 2004 and 2005 by Inc. Magazine. The company is a pillar member of BioOhio, a statewide organization of bioscience companies accelerating the bioscience and healthcare economy in Ohio. For more information, please visit www.dhiusa.com.

Christina Dierkes
Coordinator, Marketing Communications & Public Relations
p: 740-589-3300

1Gittoes, N.J.L., & Franklyn, J.A. (1998) Hyperthyroidism: Current Treatment Guidelines. Drugs, Vol. 55 Issue 4, P. 543-553.